Denosumab Biosimilar LY01011 Shows Equivalence to Reference Product for Bone Metastases
August 14th 2025Biosimilar LY01011 is equivalent to the reference product denosumab for treating bone metastases in solid tumors, demonstrating similar efficacy in reducing bone metabolism biomarkers, comparable safety profiles, and a lack of unexpected adverse reactions.
Dulaglutide Biosimilar LY05008 Shows Efficacy and Safety in Treating Type 2 Diabetes
August 7th 2025The dulaglutide biosimilar LY05008 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and immunogenicity profiles, to the reference drug dulaglutide in Chinese adults with type 2 diabetes.
Adalimumab Biosimilar Maintains Effectiveness for Patients With Arthritis and Health Care Costs
July 30th 2025Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some improvement in ultrasound findings, after switching from original adalimumab to its biosimilar, GP2017.